PRODUCT MONOGRAPH

Pr DOVOBET®
calcipotriol and betamethasone dipropionate

Ointment, 50 mcg/g calcipotriol (as monohydrate) and
0.5 mg/g betamethasone (as dipropionate)

Topical Antipsoriatic Agent
Vitamin D Analogue / Corticosteroid

LEO Pharma Inc.
Thornhill, Ontario
L3T 7W8
www.leo-pharma.ca

Control #190820

®Registered trademark of LEO Pharma A/S used under license by LEO Pharma Inc., Thornhill, ON

Date of Revision: April 4, 2016
### Table of Contents

**PART I: HEALTH PROFESSIONAL INFORMATION** .......................................................... 3
- SUMMARY PRODUCT INFORMATION ........................................................................... 3
- INDICATIONS AND CLINICAL USE .............................................................................. 3
- CONTRAINDICATIONS ................................................................................................. 3
- WARNINGS AND PRECAUTIONS ............................................................................... 4
- ADVERSE REACTIONS ................................................................................................. 7
- DRUG INTERACTIONS ................................................................................................. 9
- DOSAGE AND ADMINISTRATION ............................................................................... 9
- OVERDOSAGE .............................................................................................................. 10
- ACTION AND CLINICAL PHARMACOLOGY ................................................................. 11
- STORAGE AND STABILITY .......................................................................................... 13
- DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 13

**PART II: SCIENTIFIC INFORMATION** ....................................................................... 14
- PHARMACEUTICAL INFORMATION ............................................................................. 14
- CLINICAL TRIALS ........................................................................................................ 16
- DETAILED PHARMACOLOGY ..................................................................................... 26
- TOXICOLOGY ................................................................................................................ 32
- REFERENCES ................................................................................................................. 38

**PART III: CONSUMER INFORMATION** .................................................................... 41
PART 1: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>topical</td>
<td>Ointment, 50 mcg/g calcipotriol (as monohydrate) and 0.5 mg/g betamethasone (as dipropionate)</td>
<td>none For a complete listing see Dosage Forms, Composition and Packaging section.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

DOVOBET (calcipotriol and betamethasone dipropionate) ointment is indicated for the topical treatment of psoriasis vulgaris for up to 4 weeks.

DOVOBET should not be used on the face.

CONTRAINDICATIONS

- Patients who are hypersensitive to DOVOBET ointment, to any ingredient in the formulation or to components of the tube (see DOSAGE FORMS, COMPOSITION AND PACKAGING)
- Ophthalmic use
- Patients with known disorders of calcium metabolism
- Viral (e.g. herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis or syphilis
- Perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wounds, chicken pox and eruptions following
vaccinations

- Erythrodermic, exfoliative and pustular psoriasis

**WARNINGS AND PRECAUTIONS**

**General**

DOVOBET ointment should not be used on the face, axillae, flexures, groin, or genitals (see WARNINGS AND PRECAUTIONS/Skin).

Hypercalcemia, hypercalciuria and hypothalamic-pituitary-adrenal (HPA) axis suppression have been observed with the use of DOVOBET ointment (see WARNINGS AND PRECAUTIONS/Endocrine and Metabolism).

**Carcinogenesis and Mutagenesis**

Calcipotriol when used in combination with ultraviolet radiation (UVR) may enhance the known skin carcinogenic effect of UVR. This potential risk is based on the pre-clinical finding in mice of a reduced time to tumour formation from long term exposure of UVR and topically applied calcipotriol (see TOXICOLOGY/Carcinogenicity).

Patients who apply DOVOBET ointment to exposed skin should avoid excessive exposure to both natural and artificial sunlight (e.g. phototherapy, tanning beds, sun lamps, etc.)

**Endocrine and Metabolism**

Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticoid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid.

Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure.
Application of topical corticosteroid products including DOVOBET ointment on large areas of broken skin (i.e. open sores), on mucous membranes, in skin folds or under occlusive dressings should therefore be avoided. The use of occlusion may increase penetration of the drug into the stratum corneum, increasing the risk of adverse events. Manifestations of Cushing’s syndrome, effects on the metabolic control of diabetes mellitus (e.g. hyperglycaemia, glucosuria) and unmasking of latent diabetes mellitus can also be produced in some patients by systemic absorption of topical corticosteroids. Occlusive dressings should not be applied if body temperature is elevated.

Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression (see WARNINGS AND PRECAUTIONS/Monitoring and Laboratory Tests).

Hypercalcemia and hypercalciuria have been observed with the use of DOVOBET ointment. If hypercalemia or hypercalciuria develop, treatment should be discontinued until parameters of calcium metabolism have normalized (see WARNINGS AND PRECAUTIONS/Monitoring and Laboratory).

All of the adverse effects associated with systemic use of corticosteroids, including adrenal suppression, may also occur following topical administration of corticosteroid containing products such as DOVOBET, especially in children.

**Ophthalmologic**

DOVOBET ointment is not for ophthalmic use. DOVOBET ointment may cause eye irritation. Avoid contact with the eyes or conjunctiva.

**Skin**

DOVOBET ointment contains a potent World Health Organization (WHO) group III steroid and concurrent treatment with other corticosteroids on the same treatment area must be avoided.
DOVOBET ointment should not be used on the face, axillae, flexures, groin or genitals. The patient must be instructed in the correct use of DOVOBET ointment (e.g. washing their hands after each application) to avoid accidental transfer or application to these regions or to the mouth, mucous membranes or eyes (see DOSAGE AND ADMINISTRATION). Should facial dermatitis develop, treatment with DOVOBET ointment should be discontinued.

With long-term use, there is an increased risk of local and systemic corticosteroid adverse reactions. Treatment should be discontinued in case of corticosteroid adverse reactions related to long-term use of DOVOBET ointment (see ADVERSE REACTIONS).

When treating psoriasis with topical corticosteroid containing products, including DOVOBET ointment for a prolonged period of time, it is recommended that treatment be interrupted periodically. There may be a risk of generalised pustular psoriasis or rebound psoriasis when discontinuing corticosteroids (see ADVERSE REACTIONS). Medical supervision should therefore continue in the post-treatment period.

Concomitant skin infections should be treated with an appropriate antimicrobial agent. If the infection worsens, DOVOBET ointment should be discontinued until the infection has been adequately treated.

**Special Populations**

**Pregnant Women:** The safety of calcipotriol and/or topical corticosteroids for use during pregnancy has not been established. Although studies in experimental animals have not shown teratogenic effects with calcipotriol, studies with corticosteroids have shown teratogenic effects. The use of DOVOBET is not recommended in pregnant women.

**Nursing Women:** The safety of calcipotriol and/or topical corticosteroids for use in nursing women has not been established. It is not known whether calcipotriol can be excreted in breast milk. Batamethasone passes into breast milk, but it is not known if topical application of corticosteroid containing products, including DOVOBET, can lead to sufficient systemic absorption to produce detectable quantities in breast milk. Caution should be exercised when
prescribing DOVOBET to women who breastfeed. The patient should be instructed not to use DOVOBET on the breast when breastfeeding.

**Pediatrics (<18 years of age):** There is no clinical trial experience with the use of DOVOBET in children. Children may demonstrate greater susceptibility to systemic steroid related adverse effects due to a larger skin surface area to body weight ratio as compared to adults.

**Monitoring and Laboratory Tests**

Treatment with DOVOBET in the recommended amounts (See DOSAGE AND ADMINISTRATION) does not generally result in changes in laboratory values. However, in patients at risk for hypercalcaemia it is recommended that baseline serum calcium levels be obtained before starting treatment with subsequent monitoring of serum calcium levels at suitable intervals. If serum calcium becomes elevated, DOVOBET administration should be discontinued and serum calcium levels should be measured once weekly until they return to normal. Patients with marginally elevated serum calcium may be treated with DOVOBET, provided that serum calcium is monitored at suitable intervals.

An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, reduce the frequency of application, or substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA Axis function is generally prompt and complete upon discontinuation of topical corticosteroids (see Endocrine and Metabolism and, ACTION AND CLINICAL PHARMACOLOGY).

**ADVERSE REACTIONS**

**Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction*
information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

In clinical trials, the most common adverse reaction associated with DOVOBET (calcipotriol and betamethasone dipropionate) was pruritus. Pruritus was usually mild and no patients were withdrawn from treatment.

In a randomized, double-blind, parallel group, safety study of psoriasis patients with at least moderate disease severity, DOVOBET ointment was used intermittently on an 'as needed' basis under medical supervision (N=207). Patients were followed for up to 52 weeks. The median amount of study drug used was 15.4 g/week. The effects of DOVOBET ointment on calcium metabolism were not studied and the effects on adrenal suppression were not adequately studied. The following adverse drug reactions were reported in 1% or more of patients: pruritus (5.8%), psoriasis (5.3%), skin atrophy (based on a dermatologist’s visual assessment) (1.9%), folliculitis (1.9%), skin burning sensation (1.4%), application site skin depigmentation (1.4%), and erythema (1.0%). One case of serious flare-up of psoriasis was reported.

Other Adverse Drug Reactions
Adverse reactions observed for the individual drug substances calcipotriol and betamethasone dipropionate are described below.

Calcipotriol
Adverse reactions include application site reactions, pruritus, skin irritation, burning and stinging sensation, dry skin, erythema, rash, dermatitis, eczema, aggravated psoriasis, photosensitivity and hypersensitivity reactions including very rare cases of angioedema and facial oedema. Very rare cases of hypercalcaemia or hypercalciuria have been reported (see WARNINGS AND PRECAUTIONS).

Betamethasone dipropionate
Local reactions can occur after topical use especially during prolonged application. These include dryness, itching, burning, local irritation, skin atrophy, telangiectasia, striae, folliculitis,
hypertrichosis, perioral dermatitis, allergic contact dermatitis, depigmentation, colloid milia, maceration of the skin and secondary infection. When treating psoriasis with topical corticosteroids and following reduction or discontinuation of treatment, there are reports of the development of pustular psoriasis from chronic plaque psoriasis.

Systemic reactions due to topical use of corticosteroid containing products, including DOVOBET in adults occur infrequently but can be severe. Adrenocortical suppression, cataract, infections, impact on the metabolic control of diabetes mellitus and increase of intra-ocular pressure can occur, especially after long-term treatment. Application of DOVOBET under occlusion, on large areas or for prolonged treatment periods may result in an increased risk of systemic adverse events, and is therefore not recommended (see WARNINGS AND PRECAUTIONS).

DRUG INTERACTIONS

Drug-Drug Interactions
No drug interaction studies have been performed with DOVOBET.

DOSAGE AND ADMINISTRATION

Recommended Dose and Dosage Adjustment
DOVOBET should be applied topically to the affected areas once daily for up to 4 weeks. After satisfactory improvement has occurred, the drug can be discontinued. If recurrence takes place after discontinuation, treatment may be reinstituted.

The maximum daily dose should not exceed 15 g and the maximum weekly dose should not exceed 100 g of DOVOBET and/or other products containing calcipotriol. The total body surface area treated should not exceed 30%.

DOVOBET ointment is not recommended for use in children and adolescents below the age of 18 years.
Missed Dose
If a dose is missed, the patient should apply DOVOBET as soon as he/she remembers and then continue on as usual.

Administration
Application under occlusive dressings should be avoided since it increases systemic absorption of corticosteroids.

DOVOBET ointment should not be applied directly to the face, eyes, flexures, groin or genitals (see WARNINGS AND PRECAUTIONS/Ophthalmologic, and WARNINGS AND PRECAUTIONS/Skin).

DOVOBET ointment should be gently rubbed on the areas of your skin affected by psoriasis. Wash your hands after using DOVOBET ointment to prevent getting any on your face. No special dressing or cover is needed.

OVERDOSAGE
Due to the calcipotriol component of DOVOBET (calcipotriol and betamethasone dipropionate), excessive administration (i.e. more than the recommended weekly amount of 100 g) may cause elevated serum calcium, which should subside when treatment is discontinued. In such cases, it is recommended to monitor serum calcium levels once weekly until they return to normal. The symptoms of hypercalcemia include polyuria, constipation, muscle weakness, confusion and coma.

Excessive prolonged use of topical corticosteroid containing products, including DOVOBET ointment, may suppress pituitary-adrenal functions, resulting in secondary adrenal insufficiency which is usually reversible. If this occurs, symptomatic treatment is indicated. In cases of chronic toxicity, treatment with DOVOBET ointment must be discontinued gradually.
ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action
DOVOBET is a combination of the vitamin D analogue calcipotriol and the corticosteroid betamethasone dipropionate.

Calcipotriol is a non-steroidal antipsoriatic agent, derived from the naturally occurring vitamin D. Calcipotriol exhibits a vitamin D-like effect by competing for the 1,25(OH)2D3 receptor. Calcipotriol is as potent as 1,25(OH)2D3, the naturally occurring active form of vitamin D, in regulating cell proliferation and cell differentiation, but much less active than 1,25(OH)2D3 in its effect on calcium metabolism. Calcipotriol induces differentiation and suppresses proliferation of keratinocytes (without any evidence of a cytotoxic effect), thus reversing the abnormal keratinocyte changes in psoriasis. The therapeutic goal envisaged with calcipotriol is thus a normalization of epidermal growth.

Topical corticosteroids such as betamethasone dipropionate have anti-inflammatory, anti-pruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity is generally unclear. However, corticosteroids are thought to induce phospholipase A2 inhibitor proteins, preventing arachidonic acid release and the biosynthesis of potent mediators of inflammation.

Clinical Pharmacology
A large multicentre, randomized, double-blind clinical trial has shown DOVOBET ointment (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg/g betamethasone (as dipropionate)) administered twice daily to be more efficacious and to provide faster onset of action than either of the individual components alone (calcipotriol or betamethasone dipropionate) for the treatment of plaque psoriasis. These findings were supported by a second large, multicentre, randomised, double-blind trial comparing DOVOBET twice daily to calcipotriol and betamethasone dipropionate, each in their currently marketed formulations. A third large, multicentre, randomised, double-blind trial found DOVOBET once daily to be more efficacious
than vehicle alone and calcipotriol twice daily (betamethasone dipropionate alone was not evaluated). It was also demonstrated that once daily DOVOBET was similar to twice daily DOVOBET for most of the efficacy measures. In all three studies, DOVOBET was effective in terms of reducing PASI (Psoriasis Area and Severity Index) score and thickness of target lesions. Furthermore, a significant proportion of patients on DOVOBET achieved marked improvement or clearance at the end of 4 weeks of treatment. Clinical improvement occurred rapidly and a significant improvement was evident within 1 week of treatment. DOVOBET was well tolerated with the most common adverse reaction being mild pruritus. In one additional study, patients were treated with DOVOBET once daily for 8 weeks. Optimal population results in this study were seen between 4 and 5 weeks of treatment. The therapeutic goal envisioned with DOVOBET is to provide an effective, rapid acting topical agent for initial treatment of psoriasis and/or for treatment of flare-ups of psoriasis.

**Pharmacodynamics**

Adrenal response to ACTH was determined by measuring serum cortisol levels in patients with both extensive scalp and body psoriasis, using up to 106 g per week combined DOVOBET gel (on the scalp) and DOVOBET ointment (on the body) (study A). A borderline decrease in cortisol response at 30 minutes post ACTH challenge was seen in 5 of 32 patients (15.6%) after 4 weeks of treatment and in 2 of 11 patients (18.2%) who continued treatment until 8 weeks. In all cases, the serum cortisol levels were normal at 60 minutes post ACTH challenge. There was no evidence of change of calcium metabolism observed in these patients.

In addition, HPA axis suppression was evaluated in adult patients (n=43) with extensive psoriasis involving 15-30% of the body surface area (including the scalp) (study B). Treatment consisted of once daily application of DOVOBET gel on the body and the scalp for up to 8 weeks. Adrenal suppression, as indicated by a 30-minute post-stimulation cortisol level ≤18 mcg/dL, was observed in 3 of 43 patients (7%) after 4 weeks of treatment and in 0 of the 36 patients who provided data after 8 weeks treatment.

**Pharmacokinetics**

A pharmacokinetic study of calcipotriol ointment demonstrated that the apparent systemic
absorption over 12 hours is approximately 5.5% of the dose in normal subjects and in psoriatic patients. Topical application of corticosteroids to normal skin results in minimal absorption. Only small amounts of drug reach the dermis and are then absorbed into the systemic circulation. However, absorption may be greater when corticosteroids are applied to certain areas of the body (such as the axilla and scrotum) or if the epidermis is damaged by disease or inflammation. Continued absorption of corticosteroids may occur, even after washing, due to retention of the drug in the stratum corneum. The individual pharmacokinetics of calcipotriol and betamethasone dipropionate, are not affected by their combined presence in DOVOBET ointment. Under normal conditions of use, systemic absorption of calcipotriol and/or betamethasone dipropionate from DOVOBET is not expected to have any effects.

STORAGE AND STABILITY

Store at 5 to 25°C. Use within 12 months of first opening the tube. For easy application do not refrigerate, this is to prevent pulling of delicate skin.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Dosage Form
Ointment (faintly translucent white to yellowish ointment)

Composition
50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg/g betamethasone (as dipropionate)

Non-medicinal ingredients: -α-Tocopherol, butylhydroxytoluene, white soft paraffin, liquid paraffin and polyoxypropylene-11-stearyl ether.

Packaging
Available in 30 g, 60 g, and 120 g lacquered aluminium tubes (equipped with an aluminium membrane).
 PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name (I.N.N.): Calcipotriol hydrate
Chemical name: 9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-(1α,3β,5Z,7E,22E,24S)
Alternative chemical name: 20(R)-(3′(S)-Cyclopropyl-3′-hydroxyprop-1′(E)-enyl)-1(S),3(R)-dihydroxy-9-10-secopregna-5(Z),7(E),10(19)-triene
Laboratory code name: MC 903 or MC 903-000
Molecular formula: C_{27}H_{40}O_{3}, H_{2}O
Molecular mass: 430.6
Chirality: The calcipotriol molecular is one single stereoisomer. The absolute configuration of the chiral centres at carbon atoms nos. 1, 3, 13, 14, 17, 20 and 24 is indicated in the structural formula below.

Structural formula:
Calcipotriol hydrate
Betamethasone dipropionate

Physicochemical properties:

<table>
<thead>
<tr>
<th>Property</th>
<th>Calcipotriol hydrate</th>
<th>Betamethasone dipropionate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical Form:</strong></td>
<td>White or almost white crystalline substance.</td>
<td>White or almost white odourless powder.</td>
</tr>
<tr>
<td><strong>Solubility at room temperature</strong></td>
<td>Freely soluble in ethanol, soluble in chloroform and propylene glycol, practically insoluble in liquid paraffin. Solubility in water is 0.6 mcg/ml.</td>
<td>Freely soluble in acetone, in dioxane, in dichloromethane and in chloroform; soluble in methanol; sparingly soluble in alcohol; slightly soluble in ether; insoluble in water and in hexane.</td>
</tr>
<tr>
<td><strong>Melting point:</strong></td>
<td>166-168°C</td>
<td>176-180°C</td>
</tr>
<tr>
<td><strong>Polymorphism:</strong></td>
<td>So far no signs have indicated the existence of polymorphic forms.</td>
<td></td>
</tr>
<tr>
<td><strong>Other characteristics:</strong></td>
<td>Calcipotriol is a vitamin D derivative. It is well-known that vitamin D in solution forms a reversible temperature dependent equilibrium between vitamin D and pre-vitamin D (described in (i.e.) J Pharm Sci 1968; 57:1326). In the same way, solutions of calcipotriol establish an equilibrium with “pre-calcipotriol”. The structural formula of “pre-calcipotriol” is shown below.</td>
<td></td>
</tr>
</tbody>
</table>
CLINICAL TRIALS

A large multicentre, randomized, double-blind clinical trial has shown DOVOBET ointment (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg/g betamethasone (as dipropionate)) administered twice daily to be more efficacious and to provide faster onset of action than either of the individual components alone (calcipotriol or betamethasone dipropionate) for the treatment of plaque psoriasis. These findings were supported by a second large, multicentre, randomised, double-blind trial comparing DOVOBET twice daily to calcipotriol and betamethasone dipropionate, each in their currently marketed formulations. A third large, multicentre, randomised, double-blind trial found DOVOBET once daily to be more efficacious than vehicle alone and calcipotriol twice daily (betamethasone dipropionate alone was not evaluated). It was also demonstrated that once daily DOVOBET was similar to twice daily DOVOBET for most of the efficacy measures. In all three studies, DOVOBET was effective in terms of reducing PASI (Psoriasis Area and Severity Index) score and thickness of target lesions. Furthermore, a significant proportion of patients on DOVOBET achieved marked improvement or clearance at the end of 4 weeks of treatment. Clinical improvement occurred rapidly and a significant improvement was evident within 1 week of treatment. DOVOBET was well tolerated with the most common adverse reaction being mild pruritus. In one additional study, patients were treated with DOVOBET once daily for 8 weeks. Optimal population results in this study were seen between 4 and 5 weeks of treatment. The therapeutic goal envisioned with DOVOBET is to provide an effective, rapid acting topical agent for initial treatment of psoriasis and/or for treatment of flare-ups of psoriasis.

In a randomized, double-blind, parallel group, safety study, patients with at least moderate disease severity were given DOVOBET ointment intermittently on an 'as needed' basis under medical supervision (N=207). Patients were followed for up to 52 weeks. The median amount of study drug used was 15.4 g/week. The effects of DOVOBET ointment on calcium metabolism were not studied and the effects on adrenal suppression were not adequately studied. The following adverse drug reactions were reported in 1% or more of patients: pruritus (5.8%), psoriasis (5.3%), skin atrophy (based on a dermatologist’s visual assessment) (1.9%), folliculitis (1.9%), burning sensation (1.4%), skin depigmentation (1.4%), and erythema (1.0%). One case of serious flare-up of psoriasis was reported.
Special Studies

Effects on adrenal function and calcium metabolism were investigated in an open-label study in 35 patients with extensive psoriasis on both scalp (at least 30% of scalp area) and body (15-30% of body surface area). Patients used an average of 23.7 g/week DOVOBET gel on the scalp and an average of 40.2 g/week DOVOBET ointment on the body. Adrenal response to ACTH was determined by measuring serum cortisol levels 30 and 60 minutes after ACTH challenge. A borderline decrease in cortisol response at 30 minutes post ACTH challenge was seen in 5 of the 32 evaluable patients (15.6%) after 4 weeks of treatment and in 2 of 11 patients (18.2%) who continued treatment until 8 weeks. In all cases, the serum cortisol levels were normal at 60 minutes post ACTH challenge. There was no evidence of a change in calcium metabolism observed in these patients.

Effects on adrenal function and calcium metabolism were also investigated using only DOVOBET gel in an open-label study in 43 adult patients with extensive psoriasis involving 15-30% of the body surface area (including the scalp). Treatment consisted of once daily application of DOVOBET gel on the body and the scalp for up to 8 weeks. Adrenal response to ACTH was determined by measuring serum cortisol levels 30 and 60 minutes after ACTH challenge. The mean baseline extent of psoriasis was 20.6% of body surface area. The mean amount of study drug used over the total treatment period was 52.3 g/week (range 7.6 g/week to 92.9 g/week).

Three (7.0%) subjects had a serum cortisol ≤18 mcg/dL 30 minutes after the ACTH stimulation test at week 4. None of the 36 subjects who continued to week 8 and had samples with data had a 30 minute serum cortisol ≤18 mcg/dL. The adrenal suppression was considered borderline in two of these subjects because the 30 minute value was only slightly below the defined cut off level and the 60 minute value showed adequate response. One subject showed clear signs of adrenal suppression with a cortisol level lower than the cut off level at both 30 and 60 minutes. There were no clinically relevant changes in mean serum or urinary calcium levels. Elevated urinary calcium levels outside the normal range were observed in 2 patients (1 at 4 weeks and 1 at 8 weeks).
### SUMMARY OF CLINICAL TRIALS

<table>
<thead>
<tr>
<th>STUDY CODE</th>
<th>STUDY DESIGN</th>
<th>EVALUATION CRITERIA AND RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCB 9903 DE</td>
<td>Design: Randomised, double-blind, right/left comparison on the forearm.</td>
<td>Evaluation Criteria: Sonography was performed on day 1. Sonography and clinical assessments of atrophy, telangiectasia and erythema were performed on days 8, 15, 22 and 29. Skin biopsies were taken from 10 subjects on day 29 for morphometric determination of epidermal and dermal thickness and epidermal cell layers. Sonography and clinical assessments were repeated 2 weeks after treatment (day 43) in subjects who did not have a biopsy taken.</td>
</tr>
<tr>
<td></td>
<td>Inclusion Criteria: Healthy volunteers.</td>
<td>Results: There were no clinical signs of atrophy, telangiectasia or irritation (erythema). Sonography demonstrated skin thinning with Dovobet relative to placebo ointment but similar to betamethasone dipropionate (12.3% and 13.2% respectively) after 4 weeks of treatment. There were no histological differences in epidermal or dermal thickness between Dovobet and betamethasone dipropionate.</td>
</tr>
<tr>
<td></td>
<td>Treatment Period: Twice daily topical application for 4 weeks (28 days).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment Groups:</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Phase I:</strong> (1) Dovobet ointment (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg betamethasone (as dipropionate); (2) Betamethasone dipropionate ointment (0.5 mg/g). (n=30)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Phase II:</strong> (1) Dovobet ointment (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg betamethasone (as dipropionate); (2) Placebo ointment. (n=15)</td>
<td></td>
</tr>
</tbody>
</table>
### SUMMARY OF CLINICAL TRIALS (continued)

<table>
<thead>
<tr>
<th>STUDY CODE</th>
<th>STUDY DESIGN</th>
<th>EVALUATION CRITERIA AND RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCB 9902 FR</td>
<td><strong>Design:</strong> Single centre, randomised, double-blind, bioequivalence study according to FDA guideline for vasoconstrictor assays. <strong>Inclusion Criteria:</strong> Healthy volunteers. <strong>Treatment Period:</strong> <strong>Pilot Phase:</strong> Single 10 mcl application on the ventral forearm for 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 6 hours followed up to 24 hours. <strong>Pivotal Phase:</strong> (1) Single 10 mcl application of Dovobet and betamethasone dipropionate ointment (Diprosone*) at a dose-duration corresponding to ED₅₀ (1h04min) on two sites each per forearm. (2) Betamethasone dipropionate was also applied on two sites per forearm at dose-durations corresponding to 0.5 times ED₅₀ (32 min) and 2 times ED₅₀ (2h08min). <strong>Treatment:</strong> <strong>Pilot Phase:</strong> Diprosone* (0.5 mg/g betamethasone (as dipropionate)). (n=12) <strong>Pivotal Phase:</strong> (1) Dovobet (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg/g betamethasone (as dipropionate)) ointment; (2) Diprosone* (0.5 mg/g betamethasone (as dipropionate)). (n=90)</td>
<td><strong>Evaluation Criteria:</strong> Skin blanching (vasoconstrictor) assessed using the chromametric a value and visual scoring. <strong>Results:</strong> Pilot Part: Betamethasone dipropionate ointment (Diprosone*) produced a dose-duration dependent vasoconstriction with an ED₅₀ (half maximal response) of 1h04min., D₁ (0.5 times ED₅₀) of 32 min and D₂ (2 times ED₅₀) of 2h08 min. 67% of the included subjects were ‘detectors’ (AUC at D₁ was at least 1.25 time the AUC at D₂). Pivotal Part: Betamethasone dipropionate in Dovobet ointment is bioequivalent to the reference product, Diprosone* ointment, as the 90% confidence interval for the skin blanching response ratio (test to reference) is [0.81 ; 1.04] and within the interval [0.80 ; 1.25] as defined by the applicable FDA guideline.</td>
</tr>
</tbody>
</table>
### SUMMARY OF CLINICAL TRIALS (continued)

<table>
<thead>
<tr>
<th>STUDY CODE</th>
<th>STUDY DESIGN</th>
<th>EVALUATION CRITERIA AND RESULTS</th>
</tr>
</thead>
</table>
| MCB 9801 NL | **Design:** Single centre, open, randomised, multiple (2 application sites on the thigh) topical absorption study.  
**Inclusion Criteria:** Healthy volunteers.  
**Treatment Period:** Single 12 hour application.  
**Treatment:** Dovobet (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg/g betamethasone (as dipropionate)) ointment containing $^3$H-labelled calcipotriol. (n=4) | **Evaluation Criteria:** Pharmacokinetic parameters: Recovery of $^3$H-radioactivity from gauzes, gloves, swabs and shorts; excretion of $^3$H-radioactivity in urine and faeces; $^3$H-radioactivity levels in serum. Safety parameters: adverse events, local tolerability results, vital signs, ECG parameters and clinical laboratory parameters.  
**Results:** Excretion and recovery data suggest that there is only minimal systemic absorption of calcipotriol. The ointment was well tolerated. |
### SUMMARY OF CLINICAL TRIALS (continued)

<table>
<thead>
<tr>
<th>STUDY CODE</th>
<th>STUDY DESIGN</th>
<th>EVALUATION CRITERIA AND RESULTS</th>
</tr>
</thead>
</table>
| MCB 9901 NL | **Design:** Single centre, open, randomised, multiple (2 application sites on the thigh) topical absorption study.  
Inclusion Criteria: Healthy volunteers.  
**Treatment Period:** Single 12 hour application of $^3$H labelled ointment and single 12 hour application after 4 weeks of twice daily topical application of unlabelled ointment.  
**Treatment Groups:**  
**Group I:** Single 12 hour application of 2.5 g Dovonex (50 mcg/g calcipotriol) ointment containing $^3$H labelled calcipotriol. Four weeks (28 days) of twice daily treatment with unlabelled Dovonex. On day 36, another single 12 hour application of Dovonex containing $^3$H labelled calcipotriol. (n=6)  
**Group II:** Single 12 hour application of 2.5 g Dovobet (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg/g betamethasone (as dipropionate) ointment containing $^3$H labelled calcipotriol. Four weeks (28 days) of twice daily treatment with unlabelled Dovobet. On day 36, another single 12 hour application of Dovobet containing $^3$H labelled calcipotriol. (n=6)  
**Group III:** Single 12 hour application of 2.5 g Dovobet ointment vehicle containing $^3$H labelled calcipotriol.  
**Group IV:** Single 12 hour application of 2.5 g Dovobet ointment containing $^3$H labelled betamethasone dipropionate.  
**Group V:** Single 12 hour application of 2.5 g Dovobet ointment vehicle containing $^3$H labelled betamethasone dipropionate. | **Evaluation Criteria:**  
Pharmacokinetic parameters:  
Recovery of $^3$H radioactivity from gauzes, gloves, swabs and shorts;  
excretion of $^3$H radioactivity in urine and faeces; $^3$H radioactivity levels in serum.  
Safety parameters: adverse events, local tolerability results, vital signs, ECG parameters and clinical laboratory parameters.  
**Results:** The absorption of calcipotriol after a single application of Dovobet is similar to absorption after application of the other marketed formulation of calcipotriol (i.e. Dovonex®; 50 mcg/g calcipotriol (as monohydrate)). Thus, the safety profile of Dovonex is applicable to Dovobet.  
Betamethasone dipropionate in Dovobet does not influence the absorption rate of calcipotriol and vice versa calcipotriol does not affect the absorption of betamethasone dipropionate. Absorption of calcipotriol is similar after 4 weeks of treatment with Dovobet as it is after a single application. |
### SUMMARY OF CLINICAL TRIALS (continued)

<table>
<thead>
<tr>
<th>STUDY CODE</th>
<th>STUDY DESIGN</th>
<th>EVALUATION CRITERIA AND RESULTS</th>
</tr>
</thead>
</table>
| MCB 9802 INT | Design: Multi-centre, randomised, double-blind, vehicle-controlled, parallel-group study.  
Treatment Period: Twice daily topical application for 4 weeks of active treatment.  
Treatment Groups: (1) Combination ointment (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg betamethasone (as dipropionate); Dovobet), (n=301); (2) Calcipotriol ointment (50 mcg/g), (n=308); (3) Betamethasone dipropionate ointment (0.5 mg/g), (n=313); (4) Ointment vehicle, (n=108) | Evaluation Criteria: Change in PASI score after 4 weeks of treatment, speed of response (change in PASI score after 1 week of treatment), change in plaque thickness of a target lesion, investigators’ overall assessment of treatment response (clearance or marked improvement) at the end of treatment, patient assessment of overall treatment response, patient assessment of treatment acceptability, adverse events, and serum biochemistry.  
Results: Dovobet combination treatment was effective and provided a more rapid onset of action than either of the individual components (calcipotriol or betamethasone dipropionate). At the end of 4 weeks treatment, PASI score was reduced by 73% with Dovobet, 49% with calcipotriol, 63% with betamethasone dipropionate and 29% with vehicle (p<0.001). After 1 week of treatment PASI score was reduced by 48% with Dovobet, 28% with calcipotriol, 41% with betamethasone dipropionate and 22% with vehicle (p<0.001). The greatest reduction in target lesion thickness was observed with Dovobet. Plaque thickness was reduced by 79% with Dovobet compared to 54% with calcipotriol, 67% with betamethasone dipropionate and 27% with vehicle (p<0.001). The greatest treatment response according to the investigators’ overall assessment was also observed in the Dovobet group. With Dovobet combination treatment 76% of patients achieved clearance or marked improvement compared to 33% with calcipotriol, 56% with betamethasone dipropionate and 8% with vehicle (p<0.001). Adverse reactions associated with Dovobet were similar to reactions with betamethasone dipropionate. Mild pruritus was the most common adverse reaction. |
### SUMMARY OF CLINICAL TRIALS (continued)

<table>
<thead>
<tr>
<th>STUDY CODE</th>
<th>STUDY DESIGN</th>
<th>EVALUATION CRITERIA AND RESULTS</th>
</tr>
</thead>
</table>
| MCB 9904 INT | Design: Multi-centre, randomised, double-blind, vehicle-controlled, parallel-group study.  
Treatment Period: Phase 1: Twice daily topical application of active treatment (double-blind) for 4 weeks.  
Phase 2: twice daily maintenance therapy with Dovonex® (open-label) for 4 weeks.  
Treatment Groups:  
**Phase 1:** (1) Dovobet ointment (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg betamethasone (as dipropionate)), (n=369); (2) Dovonex® ointment (50 mcg/g calcipotriol, Leo Pharmaceutical Products), (n=365); (3) Diprosone* ointment (0.5 mg/g betamethasone (as dipropionate), Schering-Plough Ltd.), (n=363)  
**Phase 2:** Patients from each of the above groups (n=344, 332, and 344, respectively) transferred to Dovonex® ointment.  
Evaluation Criteria:  
Phase 1: Change in PASI score after 4 weeks of treatment, speed of response (change in PASI score after 1 week of treatment), change in plaque thickness of a target lesion, investigators’ overall assessment of treatment response (clearance or marked improvement) at the end of treatment, patient assessment of overall treatment response, change in redness and scaliness of a target lesion, adverse events, and serum biochemistry.  
Phase 2: general evaluation of transfer to Dovonex® maintenance therapy.  
Results:  
Dovobet combination treatment was effective and provided a more rapid onset of action than either of the individual components in their currently marketed formulations (Dovonex® and Diprosone*).  
At the end of 4 weeks treatment, PASI score was reduced by 74% with Dovobet, 55% with Dovonex®, and 61% with Diprosone* (p<0.001).  
After 1 week of treatment PASI score was reduced by 47% with Dovobet, 31% with Dovonex®, and 40% with Diprosone* (p<0.001).  
The greatest reduction in target lesion thickness was observed with Dovobet.  
Plaque thickness was reduced by 79% with Dovobet compared to 63% with Dovonex®, and 62% with Diprosone* (p<0.001).  
The greatest treatment response according to the investigators’ overall assessment was also observed in the Dovobet group.  
With Dovobet combination treatment 68% of patients achieved clearance or marked improvement compared to 39% with Dovonex®, and 47% with Diprosone* (p<0.001).  
Adverse reactions associated with Dovobet were predictable based on the individual components with mild pruritus being the most common adverse reaction.  
Patients were safely transferred to maintenance therapy with Dovonex®.  
<p>|</p>
<table>
<thead>
<tr>
<th>STUDY CODE</th>
<th>STUDY DESIGN</th>
<th>EVALUATION CRITERIA AND RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCB 9905 INT</td>
<td><strong>Design:</strong> Multi-centre, randomised, double-blind, vehicle-controlled, parallel-group study. <strong>Inclusion Criteria:</strong> Plaque psoriasis amenable to topical treatment. <strong>Treatment Period:</strong> Active topical treatment once or twice daily for 4 weeks. To maintain blinding, the once daily group received vehicle in the morning and study medication in the evening. <strong>Treatment Groups:</strong> (1) Dovobet combination ointment (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg betamethasone (as dipropionate)) once daily, (n=150); (2) Dovobet ointment twice daily, (n=234); (3) Dovonex® ointment (50 mcg/g calcipotriol) twice daily, (n=227); (4) Ointment vehicle twice daily, (n=207).</td>
<td><strong>Evaluation Criteria:</strong> Change in PASI score after 4 weeks of treatment, speed of response (change in PASI score after 1 week of treatment), change in plaque thickness of a target lesion, investigators’ overall assessment of treatment response (clearance or marked improvement) at the end of treatment, patient assessment of overall treatment response, patient assessment of treatment acceptability, change in redness and scaliness of target lesion, adverse events, and serum biochemistry. <strong>Results:</strong> Once daily Dovobet combination treatment was as effective as twice daily Dovobet treatment but more effective than twice daily Dovonex® treatment. At the end of 4 weeks, PASI score was reduced by 69% with Dovobet once daily, 59% with Dovonex® twice daily, and 27% with vehicle twice daily (p&lt;0.001). Reduction in PASI after 4 weeks of twice daily Dovobet treatment (74%) was similar to that after once daily Dovobet treatment (p=0.052). After 1 week of treatment PASI score was reduced by 46% with Dovobet once daily, 34% with Dovonex® twice daily, and 20% with vehicle twice daily (p&lt;0.001). The speed of response to Dovobet twice daily treatment was similar to that after Dovobet once daily treatment, with the reduction in PASI after one week being 48%. The greatest reduction in target lesion thickness was observed with Dovobet, with similar reductions occurring after once daily (74%) and twice daily (78%) treatment. The greatest treatment response according to the investigators’ overall assessment was also observed in the Dovobet groups, with <strong>twice daily treatment favoured over once daily</strong>. Adverse reactions associated with Dovobet were predictable based on the individual components with mild pruritus being the most common adverse reaction.</td>
</tr>
</tbody>
</table>
### SUMMARY OF CLINICAL TRIALS (continued)

<table>
<thead>
<tr>
<th>STUDY CODE</th>
<th>STUDY DESIGN</th>
<th>EVALUATION CRITERIA AND RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCB 0003 INT</td>
<td>Design: Multi-centre, randomised, double-blind, vehicle-controlled, parallel-group study.</td>
<td>Evaluation Criteria: Change in PASI score after 4 weeks of treatment, controlled disease after 4 weeks of treatment, speed of response (change in PASI score after 1 week of treatment), treatment success, and adverse events.</td>
</tr>
<tr>
<td></td>
<td>Inclusion Criteria: Plaque psoriasis amenable to topical treatment.</td>
<td>Results: Once daily Dovobet combination treatment was more effective than once daily application of its individual components or vehicle. At the end of 4 weeks, PASI score was reduced by 71% with Dovobet, 46% with calcipotriol, 57% with betamethasone dipropionate and 23% with vehicle (p&lt;0.001). The percentage of patients with controlled disease at the end of treatment was 56% for Dovobet, 22% for calcipotriol, 37% for betamethasone dipropionate and 10% for vehicle (p&lt;0.001). After 1 week of treatment PASI score was reduced by 39% with Dovobet, 23% with calcipotriol, 33% with betamethasone dipropionate and 18% with vehicle (p&lt;0.001). The proportion of patients with treatment success was 65% with Dovobet, 29% with calcipotriol, 46% with betamethasone dipropionate, and 10% with vehicle (p&lt;0.001). Adverse reactions associated with Dovobet were predictable based on the individual components with mild pruritus being the most common adverse reaction.</td>
</tr>
<tr>
<td></td>
<td>Treatment Period: Active topical treatment once daily for 4 weeks.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment Groups: (1) Dovobet combination ointment (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg betamethasone (as dipropionate) once daily, (n=490); (2) Calcipotriol ointment (50 mcg/g calcipotriol) once daily, (n=480); (3) Betamethasone dipropionate ointment (0.5 mg/g betamethasone (as dipropionate)) once daily, (n=476); (4) Vehicle ointment once daily, (n=157).</td>
<td></td>
</tr>
</tbody>
</table>
DETAILED PHARMACOLOGY

Preclinical Pharmacology

Animal Pharmacodynamic Studies with Calcipotriol: The pharmacodynamic studies performed with calcipotriol have been aimed at establishing the activity of the compound as a regulator of cell differentiation and proliferation in cells possessing the receptor for the active form of vitamin D₃, 1,25(OH)₂D₃. These studies are relevant for the intended clinical use in patients with psoriasis, due to the characteristic findings of epidermal hyperproliferation and incomplete keratinocyte differentiation in this disease.

Other current therapeutic agents act mainly through non-specific cytostatic/cytotoxic effects on the proliferating cells or suppression of underlying inflammatory and immunological reactions. In contrast, calcipotriol was shown to induce differentiation of low-differentiated human histiocytic lymphoma cells, of skin cells from newborn mice and of human keratinocytes. At the same time, proliferation was inhibited without evidence of any cytotoxic effect. The therapeutic goal envisaged with calcipotriol is thus a normalization of epidermal growth.

Calcipotriol was also found to inhibit cell proliferation induced by interleukin-1 but not by other related cellular mediators. Interleukin-1 is produced both by keratinocytes in the epidermis and by activated macrophages in the dermis. It is thought to play a pathogenetic role in psoriasis by activating both keratinocytes and immunological cells. Inhibition of interleukin-1 mediated effects in psoriatic skin by calcipotriol may therefore provide a way of regulating epidermal/dermal interactions in affected skin areas.

The pharmacodynamic studies performed *in-vitro* have shown that the activity of calcipotriol is very similar, both qualitatively and quantitatively, to that of 1,25(OH)₂D₃. This is not surprising given the structural analogy of the two compounds and the ability of calcipotriol to bind to the cellular 1,25(OH)₂D₃ receptor with the same affinity as 1,25(OH)₂D₃ itself. *In-vivo* however, the effects of calcipotriol were significantly different from those of 1,25(OH)₂D₃. The active form of vitamin D₃, 1,25(OH)₂D₃, had potent effects on calcium metabolism and overdosage resulted in hypercalcemia and hypercalciuria.
From studies performed in rats, it was shown that the effect of calcipotriol on calcium metabolism was at least 100 to 200 times lower than that of 1,25(OH)₂D₃. This low activity on calcium metabolism might be an intrinsic property of the calcipotriol molecule. However, the pharmacokinetic studies performed with calcipotriol suggested that the low activity on calcium metabolism was associated with a rapid metabolic degradation of the active compound.

**Animal Pharmacokinetic Studies with Calcipotriol:** Pharmacokinetic studies are summarized briefly here and in more detail by species in tabular form following this section. Pharmacokinetic studies with ³H-calcipotriol have been performed in rats and minipigs.

**In vivo:** Oral absorption of calcipotriol was approximately 60% in rats and 40% in minipigs. The half-life of calcipotriol was 12 minutes in rats and 60 minutes in minipigs. The major metabolite of calcipotriol MC1080 was present in the first plasma sample at 5 minutes; its half-life was 54 minutes in rats and 1.8 hours in minipigs. Drug-related radioactivity was excreted in urine and faeces and clearance was considered to be almost exclusively metabolic, as less than 5% of the administered radioactivity was excreted at the time of disappearance of all calcipotriol from plasma. Determination of the tissue distribution of calcipotriol was complicated by the appearance of ³H-H₂O from the metabolic degradation of ³H-calcipotriol. Autoradiography studies performed in rats, however, established that calcipotriol concentrations were highest in the liver, kidney and intestine. No drug-related radioactivity was present 24 hours after administration of ³H-calcipotriol.

**In vitro:** Two main metabolites of calcipotriol were observed in incubations of calcipotriol with rat liver homogenate supernatants. The two metabolites, MC1046 and MC1080, were isolated, identified and synthesized. Both metabolites were also present in supernatants from minipig, rabbit and human liver homogenates and in plasma samples from rats and minipigs. Although the necessity of using very high dosages of calcipotriol precludes the study of calcipotriol metabolism in humans, the present evidence strongly suggests that calcipotriol metabolism is qualitatively similar in rats, minipigs, rabbits and humans. In addition, both metabolites had lost most of the biological activity associated with calcipotriol thus constituting a deactivation pathway for the drug.
## IN VIVO PHARMACOKINETIC STUDIES WITH CALCIPOTRIOL

<table>
<thead>
<tr>
<th>TYPE OF STUDY</th>
<th>METHODS</th>
<th>MAJOR RESULTS AND INTERPRETATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Acute administration of $^3$H-MC903 by i.v. and oral routes to rats.</td>
<td>Female rats dosed with $^3$H-MC903, 0.10 mg/kg i.v. or 0.20 mg/kg p.o. In experiment 1, rats sacrificed at different time points for measurement of radioactivity in plasma and tissues. In experiment 2, same doses, radioactivity measured in urine and faeces during first few hours and for several days. Six rats per dose per route.</td>
<td>Rapid metabolism of MC903, with a half-life of 12 min. after i.v. Main metabolite: MC1080 in first plasma sample after 5 min; half-life of MC1080 54 min. Much lower levels after oral dosing. After both routes slow decline in the late phase due to further metabolic degradation leading to formation of $^3$H$_2$O. MC903 also metabolized to MC1046 then to more polar compounds later [possible glucuronides and sulphates, as well as putative metabolism to calcitronic acid, discussed in Study (5) below]. Renal excretion 16% (p.o.) and 26% (i.v.) of administered dose, peaking on Day 1 at 6-24 h (both routes); declined slowly in accordance with large volatile component, $^3$H$_2$O. Faecal excretion 43% (p.o.) and 40% (i.v.), also highest on the first day with both routes. Total excreted radioactivity 59% (p.o.) and 67% (i.v.); &lt;10% presumably due to exhalation of volatile components. Calculated absorption of MC903; by ratio of urinary excretion after oral and i.v. dosing, approximately 60%. Tissue levels: Highest amounts in liver, kidney and intestine; also in fat, muscle and spleen. Early measurements most accurate, ie. before formation of volatile radioactivity.</td>
</tr>
<tr>
<td>(2) Acute topical administration of $^3$H-MC903 to rats and rabbits.</td>
<td>6 rats, 2 rabbits, dosed once with topical $^3$H-MC903, 21-25 mcg/kg in rats, 9-10 mcg/kg in rabbits. Urine and faeces collected every 24 h for 144 h. Surplus ointment removed after 4 h to prevent licking. Samples taken of serum, liver, treated skin, urine, and faeces.</td>
<td>Surplus ointment removed at 4 h had accounted for about 60% of radioactivity. At 4 and 144 h less than 2% (in total) recovered from cages. Small amount of radioactivity retained in skin at 144 h (0.5-3.1%); this is approximately 30 (rats) and 200 (rabbits) times higher than levels found after i.v. dosing. Serum levels of $^3$H-MC903 were 0.2-0.6 ng-eqv/mL. This compares to 17 ng-eqv/mL after i.v. dosing of 0.1 mg/kg (see above study in rats). Percutaneous absorption based on total recovery from urine and faeces was 17%, 27% and 10% for male rats, female rats and female rabbits, respectively. Liver levels of $^3$H-MC903 ranged from 0.4-1.1 ng-eqv/g.</td>
</tr>
<tr>
<td>(3) Acute oral and i.v. dosing of $^3$H-MC903 to rats, whole-body autoradiography.</td>
<td>5 and 6 rats dosed orally and i.v., respectively, 2 controls, sacri-ficed at various times after dosing. Distribution of radio-actively labelled, non-volatile material assessed by examination of x-ray films after $\approx$ 7 months exposure to tissue sections.</td>
<td><em>I.V.</em>: Low radioactivity distributed uniformly to most tissues including brain. Higher levels in excreting organs, bile ducts, liver and to a minor extent, kidneys. <em>Oral</em>: Similar to i.v. dosing, except more radioactivity in oral cavity, oesophagus and stomach. Is noted that MC903 passes the blood-brain barrier with p.o. or i.v. dosing, that biliary excretion was evident after 15 min. with both routes of administration and no secretion to the stomach via gastric mucosa was observed. 24 h after dosing levels of non-volatile MC903-like material were very low, with no evidence for accumulation.</td>
</tr>
<tr>
<td>TYPE OF STUDY</td>
<td>METHODS</td>
<td>MAJOR RESULTS AND INTERPRETATION</td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>(4) Acute oral and i.v. dosing of $^3$H-MC903 to minipigs.</td>
<td>2 pigs/dose (1M,1F), doses 0.1 mg/kg i.v., 0.20 mg/kg oral, and placebo. Blood samples at specified times and collection of urine and faeces for 10 days. 6 weeks later females crossed over to alternate regimen, urine and faeces and certain tissues (no blood) examined for MC903.</td>
<td>Absorption with oral dosing rapid but incomplete ($\approx 40%$). No clear distribution phase following i.v. administration. Short elimination half-life of 1 h for parent. Metabolite MC1080 apparent after 5 min, with half-life of 1.8 h. No late elimination phase detected, indicating accumulation of MC903 with repeat dosing unlikely. Rebound levels observed in 1 pig at 4 hours, likely indicative of enterohepatic recirculation for parent and metabolite. Level of radioactivity after 12 h declined with half-life of $\approx 2.6$ days, likely due to $^3$H$_2$O. MC903 and metabolite MC1080 eliminated from plasma within 24 h; only 4% by renal, thus elimination mostly by metabolism. Excretion: Total cumulative recovery of 16% in urine and 44% in faeces. Tissue (mainly liver and kidney) radioactivity after 10 days mainly $^3$H$_2$O [Putative metabolic pathways discussed in study (5) below.]</td>
</tr>
<tr>
<td>(5) Rats and Minipigs treated as described in 1 and 4 above. Metabolism further studied.</td>
<td>Synthetic samples of MC1080, MC1046, MC1024 and MC1235 obtained. Plasma samples from rat and minipig obtained after dosing described above in (1) and (4). Samples analyzed by HPLC.</td>
<td>MC903 disappeared rapidly from plasma in both species, with half-lives of $\approx 12$ min (rat) and 60 min (pig). Metabolites of MC903, mainly MC1080, were observed in the first sample at 5 min after i.v. dosing. MC903, MC1080 and MC1046 account for most of the radioactivity in the samples during first hour after dosing both species. Distribution between parent and metabolites similar to in vitro studies; in rat MC1046 more prevalent after oral than i.v., possibly due to first pass. Minor metabolites more polar than MC1046 observed in both species. Content of radioactivity in eluate increases rapidly with time; 6 hours after dosing $\geq 80%$ radioactivity found in this fraction, both species, both routes; due mainly to radioactive water. Metabolism of MC903 to MC1080 and MC1046 involves oxidation at the 24-position, similar to oxidation of 1,25 dihydroxyvitamin D$_3$, active form of vitamin D$_3$. Likely that MC903 is metabolized to calcitriolic acid, similar to 1,25 dihydroxyvitamin D$_3$.</td>
</tr>
</tbody>
</table>
### IN VITRO PHARMACOKINETIC STUDIES WITH CALCIPOTRIOL

<table>
<thead>
<tr>
<th>TYPE OF STUDY</th>
<th>METHODS</th>
<th>MAJOR RESULTS AND INTERPRETATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Identification of metabolite of MC903 in rat liver homogenates.</td>
<td>Livers removed from 6-week old rats, homogenized, centrifuged and supernatants collected. Samples incubated at 37°C with MC903. Structure elucidation by proton NMR and mass spectrometry.</td>
<td>Structure elucidation by proton NMR and mass spectrometry revealed a metabolite that is identical to MC1080 detected in <em>in vivo</em> studies.</td>
</tr>
<tr>
<td>(2) Identification of metabolites in liver homogenates of rat, minipig, rabbit, and man.</td>
<td>Supernatants prepared from liver samples from rat, minipig, rabbit and man. Incubations with labelled or unlabelled MC903.</td>
<td>Metabolite identified from rat as MC1080. Also formed in substantial amounts with liver supernatants from pig, man and rabbit. Additional peak in man and rabbit due to metabolite MC1046; to a lesser extent in pig and rat. MC1080 and MC1046, along with MC903 (parent) accounted for 71%-73% of radioactivity in rat, pig and human; 7-15% due to more polar metabolites. Quantitative differences existed among the species, but the pattern of metabolism was similar for all species.</td>
</tr>
</tbody>
</table>
Clinical Pharmacology
The atrophogenic potential and dermal tolerance of DOVOBET (calcipotriol and betamethasone dipropionate) ointment was compared with that of 0.5 mg/g betamethasone (as dipropionate) ointment and placebo ointment in a randomized, double-blind, right/left comparison on the forearm of subjects (study MCB 9903 DE). Sonography demonstrated skin thinning with DOVOBET relative to placebo ointment when applied twice daily for 4 weeks. However, skin thinning with DOVOBET was similar to betamethasone dipropionate (12.3% and 13.2% respectively). There were no clinical signs of atrophy, telangiectasia or irritation (erythema). There were no histological differences in epidermal or dermal thickness between DOVOBET and betamethasone dipropionate.

The absorption and excretion balance of $^3$H-calcipotriol and $^3$H-betamethasone dipropionate was evaluated after a single application of radiolabelled DOVOBET to healthy volunteers (study MCB 9901 NL). Subjects were also treated with DOVOBET for 4 weeks and then absorption and excretion was again evaluated after a single application of radiolabelled DOVOBET. The absorption of calcipotriol after a single application of DOVOBET is similar to absorption after application of the other marketed formulation of calcipotriol (i.e. DOVONEX, 50 mcg/g calcipotriol). Thus, the safety profile of DOVONEX is applicable to DOVOBET. Betamethasone dipropionate in DOVOBET does not influence the absorption rate of calcipotriol and vice versa calcipotriol does not affect the absorption of betamethasone dipropionate. Absorption of calcipotriol is similar after 4 weeks of treatment with DOVOBET as it is after a single application.

A bioequivalence study of betamethasone dipropionate in DOVOBET ointment versus Diprosone® (Schering-Plough Ltd.) ointment, was conducted in healthy volunteers according to the FDA guideline for vasoconstrictor bioassay (study MCB 9902 FR). Betamethasone dipropionate is bioequivalent in the two preparations as the 90% confidence interval for the skin blanching response ratio (test to reference) is [0.81 ; 1.04] and within the interval of [0.80 ; 1.25] as defined by the FDA guideline.
TOXICOLOGY

Toxicologic studies are summarized briefly here and in more detail by species in tabular form following this section.

**Systemic Toxicity of Calcipotriol**

Despite the intended topical use of calcipotriol in the treatment of psoriasis, most of the toxicological studies were performed using the oral route of administration. This was done to assure maximum exposure to the compound. From these studies it was evident that toxicity associated with the administration of pharmacologically excessive doses of calcipotriol was due to the calcitropic activity of the compound. The maximum doses were 54 mcg/kg/day in rats, 18 mcg/kg/day in minipigs and 3.6 mcg/kg/day in dogs. In the acute, subacute and chronic toxicity studies the main signs of toxicity were loss of bodyweight, increases in plasma or serum calcium, creatinine and urea, renal toxicity and soft tissue calcifications. These changes resulted from the exaggerated absorption of calcium and phosphorous from the intestine and are characteristic of vitamin D overdosage. The kidney was the main target organ of toxicity and tubular lesions and calcifications were apparent after prolonged hypercalcemia in all species investigated. These types of changes, however, are not considered indicative of a human risk, since less than 1% of calcipotriol is absorbed through the skin in man and there is no evidence of calcitropic effects in man with the prescribed dose.

**Dermal Toxicity of Calcipotriol**

Dermal toxicity of calcipotriol was limited to a slight-to-moderate skin irritative effect. The studies performed with calcipotriol ointment showed that the incidence and severity of skin irritation was slightly less in the calcipotriol-treated group than in the placebo ointment group. The formulation of the ointment base is analogous to that employed for a number of steroids available for the treatment of psoriasis. Skin thinning, as seen with steroid application, was not observed with the calcipotriol ointment.

**Dermal Tolerability of DOVOBET (50 mcg/g calcipotriol (as monohydrate) plus 0.5 mg/g betamethasone (as dipropionate)):** Two dermal tolerability studies were conducted in rabbits. In the first study, no skin irritation was observed and only slight irritation attributed primarily to
Calcipotriol was observed in the second study. A gradual reduction in skin thickness was observed over 6 weeks which was attributed to betamethasone dipropionate. However, the stratum corneum of rabbit skin is much thinner than that of humans and rabbits are very sensitive to skin irritants.

**Reproduction and Mutagenicity with Calcipotriol**

Reproduction studies have shown that calcipotriol has no effect on fertility in male and female rats nor on their F₁ generation progeny. Fetal toxicity and teratogenicity studies showed no evidence of embryotoxic or teratogenic effects in rats and rabbits. Peri- and post-natal development studies indicated that calcipotriol had no toxic effects on the F₁ or F₂ generation. There was also no evidence for a mutagenic or clastogenic potential with calcipotriol.

**Carcinogenicity with Calcipotriol**

A dermal carcinogenicity study in mice showed no indications of increased carcinogenic risks. Calcipotriol solution was applied topically for up to 24 months at doses of 3, 10 and 30 mcg/kg/day (corresponding to 9, 30 and 90 mcg/m²/day). The high-dose was considered to be the Maximum Tolerated Dose for dermal treatment of mice with calcipotriol. Survival was decreased at 10 and 30 mcg/kg/day; particularly in the males. The reduced survival was associated with an increased incidence of obstructive uropathy, most probably caused by treatment-related changes in the urinary composition. This is an expectable effect of treatment with high doses of calcipotriol or other vitamin D analogues. There were no dermal effects and no dermal or systemic carcinogenicity.

**Photo(co)carcinogenicity:**

**Calcipotriol:** In a study where albino hairless mice were repeatedly exposed to both ultraviolet radiation (UVR) and topically applied calcipotriol for 40 weeks at the same dose levels as in the dermal carcinogenicity study (see above), a reduction in the time required for UVR light to induce the formation of skin tumours was observed (statistically significant in males only), suggesting that calcipotriol may enhance the effect of UVR to induce skin tumours. The clinical relevance of these findings is unknown.

**Betamethasone dipropionate:** No carcinogenicity or photocarcinogenicity studies have been performed with betamethasone dipropionate.
## ACUTE TOXICITY OF CALCIPOTRIOL

<table>
<thead>
<tr>
<th>TEST COMPOUND</th>
<th>ANIMAL</th>
<th>ROUTE / DOSAGE</th>
<th>IMPORTANT FINDINGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcipotriol (MC903)</td>
<td>Mouse</td>
<td>Oral 0-20 mg/kg i.p. 0-20 mg/kg</td>
<td>Oral and i.p. LD$<em>{50}$ in mouse and oral LD$</em>{50}$ in rat $\approx$ 20 mg/kg. i.p. LD$_{50}$ in rat $\approx$ 40 mg/kg. Clinical symptoms due to hypercalcemia; subsequent soft tissue calcification was main symptom. Cause of death: Renal failure. Organs affected: Kidney, heart, thymus and liver in rat (at $\geq$ 20 mg/kg) and kidney in mouse (at $\geq$ 5 mg/kg).</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Oral 0-40 mg/kg i.p. 0-60 mg/kg</td>
<td></td>
</tr>
<tr>
<td>MC1046 &amp; MC1080 (main metabolites of MC903)</td>
<td>Rat</td>
<td>Oral 0-80 mg/kg i.p. 0-80 mg/kg for both compounds</td>
<td>Oral and i.p. LD$<em>{50}$ for MC1046 $\approx$ 45 mg/kg. Oral LD$</em>{50}$ for MC1080 $\approx$ 35 mg/kg and $\approx$ 2X as much for i.p. Clinical symptoms due to hypercalcemia; subsequent soft tissue calcification was main symptom. Cause of death: Renal failure. Organs affected: Kidney, heart, GI tract, lung and testes (at $\geq$ 20 mg/kg).</td>
</tr>
</tbody>
</table>

## LOCAL TOLERANCE OF CALCIPOTRIOL

<table>
<thead>
<tr>
<th>TEST SYSTEM</th>
<th>ANIMAL</th>
<th>MC903 DOSAGE</th>
<th>IMPORTANT FINDINGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin irritation test</td>
<td>Rabbit (n=6)</td>
<td>5 mcg/day for 3 weeks</td>
<td>Only minor skin reactions were seen.</td>
</tr>
<tr>
<td>Skin irritation test</td>
<td>Rabbit (n=6 / group)</td>
<td>25 mcg/day ointment vs. placebo for 6 weeks</td>
<td>Treatment caused clinically well-defined to moderate skin reactions, as did placebo ointment. Reaction considered related to propylene glycol content in ointment base. No adverse histopathological changes were observed.</td>
</tr>
<tr>
<td>Skin irritation test</td>
<td>Rabbit (n=6)</td>
<td>100 mg of 50 mcg/g cream vs placebo for 6 weeks</td>
<td>Only slight irritancy developed. The irritancy developed quicker with the calcipotriol group than the placebo. The magnitude of the reactions was similar in both groups.</td>
</tr>
<tr>
<td>Skin irritation test</td>
<td>Rabbit (n=6)</td>
<td>100 mcl of 50 mcg/mL scalp solution vs placebo for 6 weeks</td>
<td>Only very slight irritancy was observed. Thickening of the epidermis was observed in areas treated with calcipotriol.</td>
</tr>
<tr>
<td>Acute eye irritation</td>
<td>Rabbit (n=3)</td>
<td>5 mcg ointment single dose</td>
<td>Only transient, fully reversible swelling of the conjunctivae was observed.</td>
</tr>
<tr>
<td>Allergenic potential maximization test</td>
<td>Guinea pig (n=10, placebo; n=20, MC903)</td>
<td>0.5-5 mcg/mL</td>
<td>MC903 was classified as a mild potential allergen.</td>
</tr>
</tbody>
</table>
## LONG-TERM TOXICITY OF CALCIPOTRIOL

<table>
<thead>
<tr>
<th>TEST COMPOUND</th>
<th>ANIMAL</th>
<th>ROUTE / DOSAGE</th>
<th>IMPORTANT FINDINGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcipotriol</td>
<td>Rat</td>
<td>Oral 0 (control), 6, 18 and 54 mcg/kg/day for 4 weeks.</td>
<td>Apart from a higher incidence of focal calcification at the cortico-medullary junction of the kidneys in the high dose animals, no other adverse effects were seen. The focal calcification can be attributed to the pharmacological effect of MC903. No mortality was seen.</td>
</tr>
<tr>
<td>(MC903)</td>
<td>(20/dose)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcipotriol</td>
<td>Dog</td>
<td>Oral 0 (control), 0.1, 0.3 and 0.9 mcg/kg/day for the first 4 weeks, ≤1.8-3.6 mcg/kg/day for the last 2 weeks. Total 6 weeks.</td>
<td>No changes were seen at doses up to 0.9 mcg/kg/day for 4 weeks, whereas raising the dose to 1.8 mcg/kg/day at week 5 and further to 3.6 mcg/kg/day at week 6 caused morphological changes in the kidneys, increases of kidney functioning and plasma calcium, all of which are attributed to the pharmacological activity of MC903. No mortality was seen.</td>
</tr>
<tr>
<td>(MC903)</td>
<td>(4/dose)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcipotriol</td>
<td>Rat</td>
<td>Dermal 0 (control) 6, 18 and 54 mcg/kg/day for 13 weeks.</td>
<td>Topical treatment for 13 weeks gave rise to slight skin reactions and some minor changes in the clinical chemistry parameters. The minimal focal calcification seen in the kidneys of all treatment group animals was a minor change which may be attributed to the calcitropic effect of MC903. The same changes occur spontaneously in lab rats. The changes recorded in the low dose group were within the level of spontaneous incidence.</td>
</tr>
<tr>
<td>(MC903)</td>
<td>(20/dose)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcipotriol</td>
<td>Rat</td>
<td>Oral 0 (control), 4, 12 and 36 mcg/kg/day for 26 weeks.</td>
<td>The target organ was identified as the kidneys. The main clinical chemistry findings were the dose-related increases in serum calcium, indicating a calcitropic effect of MC903. This was further confirmed at autopsy by increased kidney weights, lighter coloured appearance of kidneys, increased bone mineralization and renal focal and soft tissue calcification. One low dose female died on day 77, not considered as treatment-related.</td>
</tr>
<tr>
<td>(MC903)</td>
<td>(40/dose)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcipotriol</td>
<td>Minipig</td>
<td>Oral 0 (control), 1, 3 and 6 mcg/kg/day for the first 20 weeks and then up to 9-18 mcg/kg/day for the last 6 weeks. Total 26 weeks.</td>
<td>No changes were seen in low- and mid-dose animals. Increase in high-dose rapidly affected the animals by inducing distress, lethargy and bodyweight loss. These changes were accompanied by a slight decrease, still within normal range, in Hb, erythrocyte and hematocrit. Serum calcium and urea were increased, serum inorganic phosphate was decreased. At autopsy high-dose animals showed enlarged kidneys with pronounced striation of the medulla on cut surfaces. Urinary calculi were observed in 1 animal. Histopathology showed tubular necrosis and calcifications in the kidneys and the parotid gland in high-dose animals. No mortality was observed.</td>
</tr>
<tr>
<td>(MC903)</td>
<td>(6/dose)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MUTAGENICITY OF CALCIPOTRIOL

<table>
<thead>
<tr>
<th>TEST SYSTEM</th>
<th>TEST</th>
<th>MC903 DOSAGE</th>
<th>IMPORTANT FINDINGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ames Test</td>
<td>Salmonella typhimurium</td>
<td>0.01-1 mg/plate</td>
<td>MC903 was not found mutagenic in this <em>in vitro</em> bacterial test at the dose levels tested.</td>
</tr>
<tr>
<td>Mouse lymphoma TK locus assay</td>
<td>Mouse lymphoma L5178Y (TK+/−) cells</td>
<td>1-40 mcg/mL</td>
<td>MC903 demonstrates no evidence of mutagenic potential in this <em>in vitro</em> test system.</td>
</tr>
<tr>
<td>Metaphase chromosome analysis</td>
<td>Human lymphocytes</td>
<td>2-1000 mcg/mL</td>
<td>MC903 has shown no evidence of clastogenic activity in this <em>in vitro</em> cytogenetic test system.</td>
</tr>
<tr>
<td>Micronucleus test</td>
<td>Mouse bone marrow</td>
<td>1 mg/kg p.o.</td>
<td>MC903 did not show a mutagenic potential under the conditions of this <em>in vivo</em> micronucleus test.</td>
</tr>
</tbody>
</table>

REPRODUCTION AND TERATOLOGY OF CALCIPOTRIOL

<table>
<thead>
<tr>
<th>STUDY</th>
<th>ANIMAL</th>
<th>MC903 DOSAGE</th>
<th>IMPORTANT FINDINGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fertility and general reproductive performance</td>
<td>Rat (20M, 40F)</td>
<td>6-54 mcg/kg/day p.o.</td>
<td>Treatment with MC903 did not give rise to any major abnormalities in the offspring or affect the reproductive performance, morphological development or auditory, visual or behavioural systems.</td>
</tr>
<tr>
<td>Fetal development</td>
<td>Rat (32/dose)</td>
<td>6-54 mcg/kg/day p.o.</td>
<td>A few minor deviations occurred in pregnant rats given p.o. MC903 during days 6-15 of gestation, attributable to the pharmacological effects of MC903 on calcium metabolism. No teratogenic effects were observed.</td>
</tr>
<tr>
<td>Teratology</td>
<td>Rabbit (18/dose)</td>
<td>4-36 mcg/kg/day p.o.</td>
<td>At 36 mcg/kg/day of MC903 from day 6-18 of gestation, maternal toxicity was observed, characterized by deaths, bodyweight losses, reduced food intake, increased post-implantation loss, reduced mean fetal weight and increased minor ossification changes. At 12 mcg/kg/day slight signs of maternal toxicity (bodyweight loss, reduced food intake, maternal death or abortion in 2/18 animals) and reduced mean fetal weight were seen. At 4 mcg/kg/day, no adverse maternal or fetal effects were observed.</td>
</tr>
<tr>
<td>Peri- and post-natal</td>
<td>Rat (32/dose)</td>
<td>6-54 mcg/kg/day p.o.</td>
<td>Administration of MC903 to pregnant rats from day 15 of gestation to day 20 post-partum did not cause significant adverse effects on late fetal development, labour and delivery, lactation, neonatal viability and growth of the young or give rise to any major abnormalities.</td>
</tr>
</tbody>
</table>
LOCAL TOLERANCE OF DOVOBET (50 mcg/g calcipotriol plus 0.5 mg/g betamethasone (as dipropionate))

<table>
<thead>
<tr>
<th>STUDY</th>
<th>ANIMAL</th>
<th>DOVOBET DOSAGE</th>
<th>IMPORTANT FINDINGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermal tolerability</td>
<td>Rabbit</td>
<td>Once daily application of 100 mg Dovobet and 100 mg vehicle ointment on separate skin areas for 6 weeks.</td>
<td>No skin irritation was observed. Histopathological changes consisting of squamous metaplasia of pilosebaceous tissue and comedogenic activity attributable to the ointment vehicle were observed.</td>
</tr>
<tr>
<td>Dermal tolerability</td>
<td>Rabbit</td>
<td>Once daily application of 100 mg of Dovobet, calcipotriol (as monohydrate) (50 mcg/g), betamethasone (as dipropionate) (0.5 mg/g), and vehicle ointment on separate skin areas for 6 weeks.</td>
<td>Slight skin irritation attributed primarily to calcipotriol was observed. Histopathological changes consisting of squamous metaplasia of pilosebaceous tissue and comedogenic activity attributable primarily to the ointment vehicle were observed.</td>
</tr>
</tbody>
</table>
REFERENCES


5. BMS-181161 (calcipotriol): Dermal carcinogenicity study in mice (Study no. CTOX0101), data on file at LEO Pharma Inc., Thornhill, ON, L3T 7W8.

6. BMS-181161 (calcipotriol) solution: 12-month photocarcinogenesis study with ultraviolet radiation in hairless mice (Study no. CTOX0102), data on file at LEO Pharma Inc., Thornhill, ON, L3T 7W8.


15. Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T. Regulation of terminal differentiation of cultured...


33. Ristow HJ. A major factor contributing to epidermal proliferation in inflammatory skin diseases appears to be interleukin 1 or a related protein. Proc Natl Acad Sci USA 1987; 84:1940-4.


42. Clinical trial and adverse event data (including children) on file at LEO Pharma Inc., Thornhill, ON, L3T 7W8.
PART III: CONSUMER INFORMATION

PR DOVOBET®
calcipotriol and betamethasone dipropionate

This leaflet is part III of a three-part "Product Monograph" published when DOVOBET was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about DOVOBET. Contact your doctor or pharmacist if you have any questions about this drug.

ABOUT THIS MEDICATION

What the medication is used for:
DOVOBET should be used topically for up to 4 weeks to treat psoriasis plaques on your body.

DOVOBET should not be used on the face.

What it does:
DOVOBET ointment contains two medicines in one product; calcipotriol (a vitamin D-like substance) and betamethasone dipropionate (a corticosteroid) that work together to control psoriasis.

Psoriasis lesions are areas of inflamed skin where the production of skin cells is too rapid. This creates red, scaly, thick patches (plaques) of skin. Treatment is targeted at reducing signs of redness and scaling and symptoms such as itching.

Calcipotriol helps to bring the rate of skin cell growth back to normal. Betamethasone dipropionate works to reduce inflammation (redness, swelling and itching).

When it should not be used:
Do not use DOVOBET ointment:
• if you are allergic to any of the ingredients in DOVOBET ointment, or to components of the tube
• if you have high calcium levels in your body
• if you have skin infections caused by viruses (e.g. cold sores, chicken pox), a fungus (e.g. athlete’s foot, ringworm), bacteria, parasites (e.g. scabies), tuberculosis or syphilis
• on skin areas with perioral dermatitis (red mouth rash), ichthyosis (dry, scaly skin), acne (pimples), rosacea (flushed facial skin)
• on skin areas that have ulcers, open sores, thin skin, easily damaged veins, stretch marks
• to treat other types of psoriasis in the eyes

What the medicinal ingredients are:
Calcipotriol and betamethasone dipropionate

What the important nonmedicinal ingredients are:
α-tocopherol, butylhydroxytoluene, white soft paraffin, liquid paraffin, polyoxypropylene-11-stearyl ether.

What the container ingredients are:
Aluminium lacquered with epoxphenol, polyethylene.

What dosage forms it comes in:
DOVOBET is available as a topical ointment containing 50 mcg/g calcipotriol (as monohydrate) and 0.5 mg/g betamethasone (as dipropionate). Available in 30 g, 60 g, and 120 g lacquered aluminium tubes (equipped with an aluminium membrane) with re-closable polyethylene screw cap.

WARNINGS AND PRECAUTIONS

BEFORE you use DOVOBET ointment talk to your doctor or pharmacist if you:
• have diabetes
• have skin infections
• use other medicines that contain corticosteroids or calcipotriol (Vitamin D).
• are pregnant or planning to get pregnant
• are breast feeding

DOVOBET ointment is not recommended in children and adolescents under 18 years of age.

Calcipotriol in DOVOBET ointment may increase the risk of developing skin cancer caused by ultraviolet radiation (UVR).

While using DOVOBET ointment, you should avoid excessive exposure to natural or artificial sunlight (UVR) such as phototherapy, tanning beds, sunlamps, etc.

Do not use DOVOBET ointment on your face, skin folds (e.g. groin, armpit, under the breast or in the creases of the buttocks), genitals or on open sores on the skin. Do not use DOVOBET ointment in or near the eyes. DOVOBET ointment may cause eye irritation and irritation of facial skin.

Do not bandage, apply a dressing or wrap the treated skin areas after applying DOVOBET ointment on your body.

If required, your doctor may recommend a blood test to check your calcium level or the functioning of your adrenal gland.

INTERACTIONS WITH THIS MEDICATION

Before using DOVOBET ointment tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those you can buy without a prescription, especially medicines that contain a corticosteroid and/or calcipotriol.

PROPER USE OF THIS MEDICATION

Usual dose:
DOVOBET should be gently rubbed onto affected skin areas once a day for up to 4 weeks. The maximum daily dose is 15 g per day or 100 g per week of DOVOBET and/or any other products containing calcipotriol. The total body surface area treated should not exceed 30%.

**Using the ointment:**
- Remove the cap. Check that the aluminium seal has not been broken before you use it for the first time. To break the seal, use the other end of the cap to pierce the seal.
- Gently rub the ointment on the areas of your skin affected by psoriasis. Wash your hands after using DOVOBET to prevent getting any on your face. No special dressing or cover is needed.
- If you accidentally spread DOVOBET onto surrounding healthy skin, wash it off right away.
- DOVOBET is not recommended for use on your face. If you accidentally get some on your face, wash it off right away.
- Do not apply DOVOBET on large areas of damaged skin, in skin folds or under an air tight bandage/dressing. This could increase your risk of side effects.
- If DOVOBET ointment is used together with DOVONEX® cream, ointment or scalp solution, then the combined total for all products together should not be greater than 15 g per day or 100 g per week.

*For example, if you use 60 g of DOVOBET ointment in a week, you should not use more than 40 mL of DOVONEX scalp solution during the same week.*

**Overdose:**
In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

**Missed Dose:**
If you forget to use DOVOBET at the right time, use it as soon as you remember. Then go on as before.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

The most common side effect from the use of DOVOBET is itching which is usually mild.

Other side effects of using DOVOBET may include:
- local irritation
- burning and stinging sensation
- dryness
- various types of skin rash/dermatitis
- photosensitivity and hypersensitivity reactions
- red and swollen hair follicles
- lightening of skin colour
- facial rash and swelling

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncommon: worsening of psoriasis (red, scaly, thick patches of skin)</td>
<td>Only if severe</td>
<td>√</td>
</tr>
<tr>
<td>Rare: pustular psoriasis (headache, fever, chills, arthralgia, malaise, anorexia, nausea)</td>
<td>In all cases</td>
<td></td>
</tr>
<tr>
<td>Rare: adrenal effects (weakness, increased urination/thirst, fatigue, weight loss)</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Rare: skin thinning (visible veins, stretch marks)</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Very rare: allergic reaction (rash, itching, swelling, trouble breathing, dizziness)</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Very rare: high blood calcium levels (fatigue, depression mental confusion, anorexia, nausea, vomiting, constipation, increased urination and in some patients, cardiac arrhythmias)</td>
<td></td>
<td>√</td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking DOVOBET, contact your doctor or pharmacist.

**HOW TO STORE IT**

Store at 5 to 25°C. Use within 12 months of first opening the tube.
- For easy spreading do not refrigerate the ointment.
- Keep DOVOBET in a safe place where children cannot reach it.
- Keep DOVOBET away from your pets. The medicine (calcipotriol) can be fatal to dogs if eaten. If your dog eats DOVOBET contact a veterinarian immediately.
- Do not use DOVOBET past the expiry date marked on the bottom of the tube.
REPORTING SUSPECTED SIDE EFFECTS

To monitor drug safety, Health Canada through the Canada Vigilance Program collects information on serious and unexpected effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Canada Vigilance:

By toll-free telephone: 1-866-234-2345
By toll-free fax: 1-866-678-6789
Online: www.healthcanada.gc.ca/medeffect
By email: CanadaVigilance@hc-sc.gc.ca

By regular mail:
Canada Vigilance National Office
Marketed Health Products Safety and Effectiveness
Information Bureau Marked Health Products Directorate
Health Products and Food Branch
Health Canada
Tunney’s Pasture, AL 0701C
Ottawa ON K1A 0K9

NOTE: If you require information related to the management of the side effect, please contact your health care provider before notifying Canada Vigilance. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at: www.leo-pharma.ca or by contacting the sponsor, LEO Pharma Inc., at: 1-800-668-7234.

® LEO Pharma A/S used under license by LEO Pharma Inc., Thornhill, L3T 7W8

This leaflet was prepared by LEO Pharma Inc.
Last revised: April 4, 2016